ZYDUS LIFESCIENCES LIMITED

🇮🇳India

Country: 🇮🇳India

Ownership: -

Established: 1952-01-01

Employees: -

Market Cap: $13.6B

Website: http://cadilapharma.com

Clinical Trials

Desidustat in the Treatment of Chemotherapy Induced Anemia

Phase 1

Completed

Conditions: Anemia of Chronic Kidney Disease
Chemotherapy Effect

Interventions: Drug: Desidustat

First Posted Date: 2020-12-14

Last Posted Date: 2022-05-18

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 24

Registration Number: NCT04667533

Locations: 🇮🇳
HCG Manavata Cancer Centre,, Nashik, Mahar Ashtra, India

Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)

Phase 2

Terminated

Conditions: Covid19

Interventions: Drug: Pegylated Interferon-α2b
Other: Standard of Care

First Posted Date: 2020-07-21

Last Posted Date: 2022-07-12

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 7

Registration Number: NCT04480138

Locations: 🇲🇽
Avant Sante site 2, Zapopan, Jalisco, Mexico
🇲🇽
Avant Sante Site 1, Monterrey, Mexico

Desidustat in the Management of COVID-19 Patients

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Desidustat
Other: Standard of Care

First Posted Date: 2020-07-09

Last Posted Date: 2021-04-23

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 24

Registration Number: NCT04463602

Locations: 🇲🇽
Avant Sante Site 1, Monterrey, Mexico

Desidustat in the Treatment of Anemia in CKD on Dialysis Patients

Phase 3

Completed

Conditions: Chronic Kidney Disease Stage 5 on Dialysis

Interventions: Drug: Desidustat Oral Tablet
Drug: Epoetin Alfa

First Posted Date: 2020-01-02

Last Posted Date: 2021-11-24

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 392

Registration Number: NCT04215120

Locations: 🇮🇳
Karnavati Hospital Pvt.Ltd, Ahmedabad, Gujarat, India
🇮🇳
Chopda Medicare & Research Centre Pvt. Ltd, Nashik, Maharashtra, India
🇮🇳
Star Hospital, Hyderabad, Telangana, India

and more 4 locations

Desidustat in the Treatment of Anemia in CKD

Phase 3

Completed

Conditions: Chronic Kidney Disease Stage 3
Anemia
Chronic Kidney Disease Stage 4
Chronic Kidney Disease Stage 5

Interventions: Drug: Desidustat Oral Tablet
Drug: Darbepoetin Alfa

First Posted Date: 2019-07-09

Last Posted Date: 2021-11-24

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 588

Registration Number: NCT04012957

Locations: 🇮🇳
Sawai Man Singh (SMS) Medical College and Hospital, Jaipur, Rajasthan, India
🇮🇳
Max Super Specialty Hospital, New Delhi, Delhi, India
🇮🇳
Eternal Hospital, Jaipur, Rajasthan, India

and more 27 locations

Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PKs) of ZYDPLA1 Following Oral Administration in Healthy Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus

Interventions: Drug: ZYDPLA1 tablet
Drug: Placebo tablet

First Posted Date: 2015-12-03

Last Posted Date: 2015-12-03

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 84

Registration Number: NCT02620592

Locations: 🇺🇸
Profil Institute for Clinical Research, Chula Vista, California, United States

To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel

Phase 3

Completed

Conditions: Acne Vulgaris

Interventions: Drug: Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel
Drug: DUAC® Gel
Drug: Placebo

First Posted Date: 2013-12-09

Last Posted Date: 2020-10-14

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 850

Registration Number: NCT02005666

Locations: 🇺🇸
Research Across America, Santa Ana, California, United States
🇺🇸
International Dermatology Research, Inc., Miami, Florida, United States
🇺🇸
Skin Specialists, PC, Omaha, Nebraska, United States

and more 33 locations

A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ZYD1, Following Subcutaneous Administration in Healthy Volunteers

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: ZYD1
Drug: Placebo

First Posted Date: 2013-10-31

Last Posted Date: 2013-10-31

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 56

Registration Number: NCT01972893

Locations: 🇮🇳
Zydus Research Centre, Survey No. 396/403, Opp. Sarvotam Hotel, Nr. Nova Petrochemicals, Sarkhej-Bavla N.H. No. 8A, Village : Moraiya,, Ahmedabad, Gujarat, India

A Clinical Study to Evaluate the Safety,Tolerability and PK of ZYT1, Following Oral Administration in Healthy Volunteers

Phase 1

Terminated

Conditions: Obesity
Lipid Disorders

Interventions: Drug: ZYT1
Drug: Placebo tablets

First Posted Date: 2012-03-02

Last Posted Date: 2015-11-24

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 24

Registration Number: NCT01543269

Locations: 🇮🇳
Zydus Research Centre, Cadila Healthcare Limited, Ahmedabad-, Gujarat, India

A Clinical Trial to Evaluate the Safety and Efficacy of ZYH7 Compared to Fenofibrate in Patients With Dyslipidemia

Phase 2

Completed

Conditions: Dyslipidemia
Hypertriglyceridemia

Interventions: Drug: ZYH7
Drug: Fenofibrate

First Posted Date: 2012-02-27

Last Posted Date: 2013-10-28

Lead Sponsor: Zydus Lifesciences Limited

Target Recruit Count: 109

Registration Number: NCT01539616

Locations: 🇮🇳
Shree Nidan Hospital, Clinical trial department, First floor, 27-28 Vidhyut nagar-A, Ajmer road, Jaipur, Rajasthan, India
🇮🇳
Gastrocare Clinic,Ground floor, Karansinhji Main Road,, Rajkot, Gujarat, India
🇮🇳
Bhatia Hospital, Tardeo Road,Room no 19, Basement floor,Research room,, Mumbai, Maharashtra, India

and more 15 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy